-
1
-
-
33745927137
-
How may anticancer chemotherapy with fluorouracil be individualised?
-
S. A. Ploylearmsaeng, U. Fuhr, A. Jetter. How may anticancer chemotherapy with fluorouracil be individualised? Clin. Pharmacokinet. 2006, 45, 567.
-
(2006)
Clin. Pharmacokinet.
, vol.45
, pp. 567
-
-
Ploylearmsaeng, S.A.1
Fuhr, U.2
Jetter, A.3
-
2
-
-
0032978473
-
Can pharmacokinetic monitoring improve clinical use of fluorouracil?
-
A. M. Young, S. Daryanani, D. J. Kerr. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin.Pharmacokinet. 1999, 36, 391.
-
(1999)
Clin.Pharmacokinet.
, vol.36
, pp. 391
-
-
Young, A.M.1
Daryanani, S.2
Kerr, D.J.3
-
3
-
-
0031790577
-
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology
-
R. B. Diasio. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park) 1998, 12, 23.
-
(1998)
Oncology (Williston Park)
, vol.12
, pp. 23
-
-
Diasio, R.B.1
-
5
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
-
M. Miwa, M. Ura, M. Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, H. Ishitsuka. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34, 1274.
-
(1998)
Eur. J. Cancer
, vol.34
, pp. 1274
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
Sawada, N.4
Ishikawa, T.5
Mori, K.6
Shimma, N.7
Umeda, I.8
Ishitsuka, H.9
-
6
-
-
33947301765
-
Capecitabine: In advanced gastric or oesophagogastric cancer
-
S. Dhillon, L. J. Scott. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs 2007, 67, 601.
-
(2007)
Drugs
, vol.67
, pp. 601
-
-
Dhillon, S.1
Scott, L.J.2
-
8
-
-
0029790295
-
Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
-
Y. Takebayashi, S. Akiyama, S. Akiba, K. Yamada, K. Miyadera, T. Sumizawa, Y. Yamada, F. Murata, T. Aikou. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl Cancer. Inst. 1996, 88, 1110.
-
(1996)
J. Natl Cancer. Inst.
, vol.88
, pp. 1110
-
-
Takebayashi, Y.1
Akiyama, S.2
Akiba, S.3
Yamada, K.4
Miyadera, K.5
Sumizawa, T.6
Yamada, Y.7
Murata, F.8
Aikou, T.9
-
9
-
-
10744232035
-
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients
-
X. Pivot, E. Chamorey, E. Guardiola, N. Magne, A. Thyss, J. Otto, B. Giroux, Z. Mouri, M. Schneider, G. Milano. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann. Oncol. 2003, 14, 1578.
-
(2003)
Ann. Oncol.
, vol.14
, pp. 1578
-
-
Pivot, X.1
Chamorey, E.2
Guardiola, E.3
Magne, N.4
Thyss, A.5
Otto, J.6
Giroux, B.7
Mouri, Z.8
Schneider, M.9
Milano, G.10
-
10
-
-
0031890613
-
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis
-
M. C. Etienne, E. Chatelut, X. Pivot, M. Lavit, A. Pujol, P. Canal, G. Milano. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur. J. Cancer 1998, 34, 92.
-
(1998)
Eur. J. Cancer
, vol.34
, pp. 92
-
-
Etienne, M.C.1
Chatelut, E.2
Pivot, X.3
Lavit, M.4
Pujol, A.5
Canal, P.6
Milano, G.7
-
11
-
-
0031696544
-
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: Results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas
-
R. Fety, F. Rolland, M. Barberi-Heyob, A. Hardouin, L. Campion, T. Conroy, J. L. Merlin, A. Riviere, G. Perrocheau, M. C. Etienne, G. Milano. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 1998, 4, 2039.
-
(1998)
Clin. Cancer Res.
, vol.4
, pp. 2039
-
-
Fety, R.1
Rolland, F.2
Barberi-Heyob, M.3
Hardouin, A.4
Campion, L.5
Conroy, T.6
Merlin, J.L.7
Riviere, A.8
Perrocheau, G.9
Etienne, M.C.10
Milano, G.11
-
12
-
-
13344269002
-
Relationshipbetween5-fluorouracil (5-FU)doseintensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
-
E. C. Gamelin, E. M. Danquechin-Dorval,Y. F. Dumesnil, P. J. Maillart, M. J.Goudier, P. C. Burtin, R. G. Delva, A. H. Lortholary, P.H.Gesta, F. G. Larra.Relationshipbetween5-fluorouracil (5-FU)doseintensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996, 77, 441.
-
(1996)
Cancer
, vol.77
, pp. 441
-
-
Gamelin, E.C.1
Danquechin-Dorval, E.M.2
Dumesnil, Y.F.3
Maillart, P.J.4
Goudier, M.J.5
Burtin, P.C.6
Delva, R.G.7
Lortholary, A.H.8
Gesta, P.H.9
Larra, F.G.10
-
13
-
-
0028357629
-
Relationship between fluorouracil systemic exposure and tumor response and patient survival
-
G. Milano, M. C. Etienne, N. Renee, A. Thyss, M. Schneider, A. Ramaioli, F. Demard. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol. 1994, 12, 1291.
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 1291
-
-
Milano, G.1
Etienne, M.C.2
Renee, N.3
Thyss, A.4
Schneider, M.5
Ramaioli, A.6
Demard, F.7
-
14
-
-
54949148391
-
Influence of capecitabine absorption on its metabolites pharmacokinetics: A bioequivalence study
-
L. Chaigneau, B. Royer, D. Montange, T. Nguyen, T. Maurina, C. Villanueva, M. Demarchi, C. Borg, C. Fagnoni-Legat, J. P. Kantelip, X. Pivot. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. Ann. Oncol. 2008, 19, 1980.
-
(2008)
Ann. Oncol.
, vol.19
, pp. 1980
-
-
Chaigneau, L.1
Royer, B.2
Montange, D.3
Nguyen, T.4
Maurina, T.5
Villanueva, C.6
Demarchi, M.7
Borg, C.8
Fagnoni-Legat, C.9
Kantelip, J.P.10
Pivot, X.11
-
15
-
-
0024512054
-
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
-
J. Santini, G. Milano, A. Thyss, N. Renee, P. Viens, P. Ayela, M. Schneider, F. Demard. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 1989, 59, 287.
-
(1989)
Br. J. Cancer
, vol.59
, pp. 287
-
-
Santini, J.1
Milano, G.2
Thyss, A.3
Renee, N.4
Viens, P.5
Ayela, P.6
Schneider, M.7
Demard, F.8
-
16
-
-
45849124567
-
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites
-
T. Besnard, N. Renee, M. C. Etienne-Grimaldi, E. Francois, G. Milano. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 870, 117.
-
(2008)
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
, vol.870
, pp. 117
-
-
Besnard, T.1
Renee, N.2
Etienne-Grimaldi, M.C.3
Francois, E.4
Milano, G.5
-
17
-
-
0003484310
-
-
FDA. Center for Drug Evaluation and Research. Food and Drug Administration
-
FDA. Guidance for Industry. Bioanalytical Method Validation. In: Center for Drug Evaluation and Research. Food and Drug Administration, 2001.
-
(2001)
Guidance for Industry. Bioanalytical Method Validation
-
-
-
18
-
-
0032986050
-
The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds
-
R. Bonfiglio, R. C. King, T. V. Olah, K. Merkle. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 1999, 13, 1175.
-
(1999)
Rapid Commun. Mass Spectrom.
, vol.13
, pp. 1175
-
-
Bonfiglio, R.1
King, R.C.2
Olah, T.V.3
Merkle, K.4
-
19
-
-
30444448196
-
Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis
-
B. K. Matuszewski. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006, 830, 293.
-
(2006)
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
, vol.830
, pp. 293
-
-
Matuszewski, B.K.1
-
20
-
-
77953350741
-
Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry
-
DOI: 10.1016/j.chroma.2009.11.060
-
F.Gosetti, E.Mazzucco, D.Zampieri, M.C.Gennaro. Signal suppression/enhancement in high-performance liquid chromatography tandem mass spectrometry. J. Chromatogr. A 2009, DOI: 10.1016/j.chroma.2009.11.060.
-
(2009)
J. Chromatogr. A
-
-
Gosetti, F.1
Mazzucco, E.2
Zampieri, D.3
Gennaro, M.C.4
-
21
-
-
0038574979
-
Ion suppression in mass spectrometry
-
T. M. Annesley. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041.
-
(2003)
Clin. Chem.
, vol.49
, pp. 1041
-
-
Annesley, T.M.1
-
22
-
-
58149112644
-
Effect of eluent on the ionization process in liquid chromatography-mass spectrometry
-
R. Kostiainen, T. J. Kauppila. Effect of eluent on the ionization process in liquid chromatography-mass spectrometry. J. Chromatogr. A 2009, 1216, 685.
-
(2009)
J. Chromatogr. A
, vol.1216
, pp. 685
-
-
Kostiainen, R.1
Kauppila, T.J.2
-
23
-
-
26844581328
-
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies
-
S.M. Guichard, I.Mayer, D. I. Jodrell. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 826, 232.
-
(2005)
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
, vol.826
, pp. 232
-
-
Guichard, S.M.1
Mayer, I.2
Jodrell, D.I.3
-
24
-
-
0032940053
-
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage
-
E. Gamelin, M. Boisdron-Celle, V. Guerin-Meyer, R. Delva, A. Lortholary, F. Genevieve, F. Larra, N. Ifrah, J. Robert. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 1999, 17, 1105.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 1105
-
-
Gamelin, E.1
Boisdron-Celle, M.2
Guerin-Meyer, V.3
Delva, R.4
Lortholary, A.5
Genevieve, F.6
Larra, F.7
Ifrah, N.8
Robert, J.9
-
25
-
-
57449112750
-
Overcoming matrix effects in liquid chromatographymass spectrometry
-
A. Cappiello, G. Famiglini, P. Palma, E. Pierini, V. Termopoli, H. Trufelli. Overcoming matrix effects in liquid chromatographymass spectrometry. Anal. Chem. 2008, 80, 9343.
-
(2008)
Anal. Chem.
, vol.80
, pp. 9343
-
-
Cappiello, A.1
Famiglini, G.2
Palma, P.3
Pierini, E.4
Termopoli, V.5
Trufelli, H.6
-
26
-
-
77950204871
-
A new, validated HPLC-MS/MS method for thesimultaneous determination of the anti-cancer agent capecitabine and itsmetabolites: 5′-deoxy-5- fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma
-
L. D. Vainchtein, H. Rosing, J. H. Schellens, J. H. Beijnen. A new, validated HPLC-MS/MS method for thesimultaneous determination of the anti-cancer agent capecitabine and itsmetabolites: 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed. Chromatogr. 2010, 24, 374.
-
(2010)
Biomed. Chromatogr.
, vol.24
, pp. 374
-
-
Vainchtein, L.D.1
Rosing, H.2
Schellens, J.H.3
Beijnen, J.H.4
|